- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Friendswood Today
By the People, for the People
Castle Biosciences Publishes Validation Study for AdvanceAD-Tx Test
The study in the Journal of the American Academy of Dermatology demonstrates the test's effectiveness.
Published on Feb. 27, 2026
Got story updates? Submit your updates here. ›
Castle Biosciences, Inc., a genomic diagnostics company, has published the results of a prospective validation study for its AdvanceAD-Tx test in the Journal of the American Academy of Dermatology. The study demonstrates the test's ability to accurately predict treatment response in patients with advanced atopic dermatitis.
Why it matters
The AdvanceAD-Tx test could help dermatologists make more informed treatment decisions for patients with severe, treatment-resistant atopic dermatitis, a chronic and debilitating skin condition. Accurate prediction of treatment response is crucial for this patient population, as current therapies can be costly and have significant side effects.
The details
The prospective validation study included 200 patients with advanced atopic dermatitis. The AdvanceAD-Tx test was able to accurately predict treatment response in 90% of cases, helping clinicians determine the most appropriate therapy for each patient.
- The study was published on February 19, 2026 in the Journal of the American Academy of Dermatology.
The players
Castle Biosciences, Inc.
A genomic diagnostics company that develops and commercializes tests to guide patient care.
The takeaway
The successful validation of the AdvanceAD-Tx test is a significant development in the management of advanced atopic dermatitis, as it provides a valuable tool to help dermatologists personalize treatment and improve outcomes for this difficult-to-treat patient population.
